PCFiT™ Recombinant Protein Technology is Worg's globally exclusive AIT drug development platform. By identifying the corresponding sensitizing protein T-cell and B-cell epitopes based on allergen characteristics, it produces peptide carrier fusion proteins that efficiently induce protective immune responses, achieving optimal IgG immunogenicity and, thus, safer and more effective allergy immunotherapy.
Compared to traditional allergen-extracted AIT drugs, PCFiT™ recombinant proteins offer outstanding advantages, including high IgG induction efficacy, minimal side effects, and ease of use.
Early clinical data show that patients treated with PCFiT™ AIT drugs require only 3-5 doses to achieve long-term relief from allergy symptoms.
Based on the PCFiT™ platform, Worg has completed the development and overseas clinical trials for several global First-in-Class (FIC) pipeline products.
WP1048 is a biopharmaceutical product used to treat grass pollen allergies. Grass pollen allergies are particularly common in temperate regions, especially in Europe and North America.
The active ingredient of WP1048 consists of four recombinant proteins generated using the PCFiT™ technology. These proteins serve as antigens, inducing immune responses against the four major grass pollen allergens: Phl p 1, Phl p 2, Phl p 5, and Phl p 6. Research has shown that the antigenic epitopes of these four grass pollen allergens exhibit significant cross-reactivity with allergens from other grass species.
For the WP1048 project, four Phase I/II clinical trials have been completed, and preliminary results confirm the product's safety and clinical efficacy.
WP1075 is a biopharmaceutical designed to treat cat dander allergies. Pet dander is one of the fastest-growing allergens globally, with the latest epidemiological data indicating that nearly 20% of AR patients in China are allergic to pet dander.
The active ingredient of WP1075 is developed using AI algorithms to screen antigen sequences, identify the final candidate peptide core inducing epitopes, and complete spatial reconstruction.
Preclinical studies have demonstrated a significant ability to block the binding of antigens to IgE and induce specific IgG immune responses. Treatment can be completed with just 2-3 injections, significantly improving the accessibility of AIT.
The drug's PCC has been completed and is about to enter clinical trials.
Scan
WeChat official account
A wholly-owned subsidiary of Worg PHARMA
